Client: Large Biotech.
Our client needed a comprehensive assessment of the clinical and commercial potential of several indications for a preclinical asset to help inform clinical development planning, kick-off the LCM process with early buy-in from all internal stakeholders and develop a set of criteria for future go/no-go decisions.
Our Solution
GlobalData Custom Solutions conducted the project in multiple phases. First, we created a long-list of potential indications and provided detail on the scientific and clinical evidence available for each.
Second, we prioritized the top 8 indications based on the client’s therapy area interests and the scientific rationale.
Third, we created high-level commercial and clinical opportunity assessments to serve as a pre-read and developed prioritization criteria for use in the fourth phase, an interdisciplinary indication prioritization workshop.
Outcome
- Our project delivered cross-functional alignment on clinical development planning including:
- Prioritization of a lead indication and the next clinical steps to take
- KIQs to track and an understanding of how competitive outcomes may affect future decisions
Our consultants work closely with you to understand requirements and develop a tailored approach and deliverables.
